Home›Trial›NCT07425392
NCT07425392Phase 3RECRUITING

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

Study Summary

The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.

Conditions
Pneumococcal Vaccines
Interventions / Drugs
31-valent pneumococcal conjugate vaccinePCV20
View on ClinicalTrials.gov ↗
Sponsor
PCVX
Vaxcyte Inc
Vaccines
D37/100
Study Details
Enrollment720 participants
Primary Completion—
Lead SponsorVaxcyte, Inc.
Data Retrieved2026-04-11 04:24:14.205321+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 720 participants
Sponsor Catalyst Profile

Vaxcyte Inc (PCVX) is the sponsoring company for this trial. BiotechSign currently grades this company D (37/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

PCVX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.